---
document_datetime: 2023-09-21 16:59:46
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps/photobarr-epar-procedural-steps-taken-authorisation_en.pdf
document_name: photobarr-epar-procedural-steps-taken-authorisation_en.pdf
version: success
processing_time: 0.5392387
conversion_datetime: 2025-12-29 21:03:17.566121
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## BACKGROUND INFORMATION ON THE PROCEDURE

## 1. Submission of the dossier

The company Axcan Pharma International BV submitted on 8 April 2002 an application for Marketing Authorisation  to  the  European  Agency  for  the  Evaluation  of  Medicinal  Products  (EMEA)  for PhotoBarr,  through  the  centralised  procedure.  PhotoBarr  was  designated  as  an  orphan  medicinal product (EU/3/02/086) on 6 March 2002.

The Rapporteur and Co-Rapporteur appointed by the CPMP were:

•

- The applicant submitted the responses to the 2 nd CPMP list of outstanding issues on 31 October 2003.

Medicinal product no longer authorised Rapporteur: Prof Rolf Bass Prof Tilman Ott Co-Rapporteur: Dr Eric Abadie Licensing status: PhotoBarr has been given a Marketing Authorisation in Canada on 14 March 2003 and in USA on 1 August 2003. 2. Steps taken for the assessment of the product · The procedure started on 20 May 2002. · The Rapporteur's first assessment report was circulated to all CPMP Members on 19 August 2002. The Co-Rapporteur's first Assessment Report was circulated to all CPMP Members on 9 August 2002. · During  the  meeting  on  17-19  September  2002  the  CPMP  agreed  on  the  consolidated  list  of questions to be sent to the company. The final consolidated List of Questions was sent to the company on 19 September 2002. · The summary report of the inspection carried out at the manufacturing site Wyeth-Ayerst Inc, Puerto Rico, between 11-15 November 2002 was issued on 23 December 2002. · The applicant submitted the responses to the consolidated List of Questions on 19 March 2003. · The Rapporteurs circulated the Joint Assessment Report on the applicant's responses to the List of Questions to all CPMP members on 20 May 2003. · During  the  CPMP  meeting  on  20-22  May  2003  the  CPMP  agreed  on  the  list  of  outstanding issues to be addressed in writing and /or in an oral explanation by the applicant. · The  applicant  submitted  the  responses  to  the  CPMP  list  of  outstanding  issues  on  28  August 2003. · The Rapporteurs circulated the Joint Assessment Report on the applicant's responses to the list of outstanding issues to call all CPMP members on 26 September 2003. During the CPMP meeting on 21-23 October 2003 the CPMP agreed on a 2 nd list of outstanding issues to be addressed in writing and/or in an oral explanation by the applicant.

- The summary report of the inspection carried out at the manufacturing site Wyeth-Ayerst Inc, Puerto Rico, between 25-28 November 2003 was issued on December 2003.
- The Rapporteurs circulated the Joint Assessment Report on the applicant's responses to the list of outstanding issues to all CPMP members on 2 December 2003.

<!-- image -->

<div style=\"page-break-after: always\"></div>

- During  the  meeting  on  16-18  December  2003  the  CPMP,  in  the  light  of  the  overall  data submitted  and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for granting a Marketing Authorisation to PhotoBarr on 18 December 2003.
- The CPMP opinions were forwarded, in all official languages of the European Union, to the European Commission, which adopted the corresponding Decisions on 25 March 2004.

<!-- image -->